
Opinion|Videos|August 9, 2024
Future Predictions for Intravenous and Subcutaneous Biologics
An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How has the introduction of IV biosimilars impacted your treatment decisions? Do you see a role for subcutaneous biosimilars in the future?
- Do you foresee IV and subcutaneous route of administration always having a role moving forward? How do you see the treatment landscape changing?
Advertisement
Related to this article

A Massachusetts federal court threw out HRSA grant terms that kept Ryan White clinics from offering gender-affirming care to patients with HIV.

Only 43% of community oncologists feel very comfortable with new immunotherapies. Prerna Mewawalla, M.D., of Allegheny Health Network talks safety protocols and trial access.

Among 16 Black transgender women, 15 with HIV, risk awareness, comfort, provider trust and support shaped whether they completed HRA, according to a new qualitative study.

A Centene OB-GYN and an AAFP family physician explain how health plans, primary care and policy can help close rural maternity care gaps.

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working
The FDA granted accelerated approval to GSK's Nelkarmi for previously treated ALK-positive NSCLC, the company's second lung cancer approval this year.

A pooled review of 40 studies tied type 2 diabetes to a 53% higher Alzheimer’s risk, with incidence more than doubling when clinicians made the diagnosis.

Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Quick Q&A: Sarah Klein on scrutinizing PBM contracts
2
Closing rural maternity care gaps starts close to home, Centene and AAFP leaders say
3
Federal judge vacates HRSA limits on gender-affirming care in Ryan White HIV program
4
For transgender women with HIV, risk awareness and provider trust shape anal cancer follow-up
5



